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Background/purpose: Intensity-modulated proton therapy (IMPT) is highly sensitive to anatomical varia-
tions which can cause inadequate target coverage during treatment. Available mitigation techniques
include robust treatment planning and online-adaptive IMPT. This study compares a robust planning
strategy to two online-adaptive IMPT strategies to determine the benefit of online adaptation.
Materials/methods: We derived the robustness settings and safety margins needed to yield adequate tar-
get coverage (V95%  98%) for >90% of 11 patients in a prostate cancer cohort (88 repeat CTs). For each
patient, we also adapted a non-robust prior plan using a simple restoration and a full adaptation method.
The restoration uses energy-adaptation followed by a fast spot-intensity re-optimization. The full adap-
tation uses energy-adaptation followed by the addition of new spots and a range-robust spot-intensity
optimization.
Dose was prescribed as 55 Gy(RBE) to the low-dose target (lymph nodes and seminal vesicles) with a
boost to 74 Gy(RBE) to the high-dose target (prostate). Daily patient set-up was simulated using
implanted intra-prostatic markers.
Results: Margins of 4 and 8 mm around the high- and low-dose target regions, a 6 mm setup error and a
3% range error were found to obtain adequate target coverage for all repeat CTs of 10/11 patients (94.3%
of all 88 repeat CTs).
Both online-adaptive strategies yielded V95%  98% and better OAR sparing in 11/11 patients. Median
OAR improvements up to 11%-point and 16%-point were observed when moving from robust planning to
respectively restoration and full adaption.
Conclusion: Both full plan adaptation and simple dose restoration can increase OAR sparing besides better
conforming to the target criteria compared to robust treatment planning.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 151 (2020) 228–233 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Due to its characteristic Bragg Peak, intensity-modulated pro-
ton therapy (IMPT) can deliver dose locally, avoiding low dose
baths and improving dose conformality. These Bragg Peaks how-
ever also make IMPT sensitive to anatomical variations such as
changes in density, organ-shape and location [1–3]. Twomitigation
strategies accounting for such uncertainties are robust treatment
planning and online-adaptive IMPT. Robust treatment planning is
a passive strategy which preemptively includes errors scenarios
in the optimization possibly combined with safety margins to
account for anatomical variations [4–6]. Conversely, online-
adaptive IMPT is an active strategy taking the optimized plan
and adapting it to better fit the daily anatomy and undo the effects
of density variations prior to each fraction [7–13].Making a treatment plan more robust inevitably results in
increased doses to healthy tissues [14]. Conversely, online-
adaptive planning aims at maintaining an adequate target volume
coverage, while minimizing the dose to the organs at risk (OARs)
for each fraction. In previous work, we developed online-
adaptive treatment planning methods which are feasible for clini-
cal implementation. Starting with the development of a dose
restoration method [8], we could restore the initial dose distribu-
tion from a dose distribution distorted due to differences in den-
sity. Subsequently, we extended this into a full, but sufficiently
fast, automated plan adaptation method to adapt the plan to the
daily shape and position of the target volume and OARs [10,12].
We demonstrated that both methods can achieve acceptable target
coverage for (most of) the fractions and simultaneously yield OAR
doses close to what can be achieved with a fully optimized treat-
ment plan generated without time constraints [8,10,12].
So far, however, the proposed adaptive treatments have not been
compared to non-adaptive treatments for which robust treatment
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omy. Such a comparison is complex, because although individual
uncertainties suchas intra-fractionmotionandpositioningvariations
have been described in literature, information on how to combine
these in robustness settings and safety margins in robust optimiza-
tion is still lacking. A comparison is nevertheless recommendable to
establish the value of online-adaptive treatment approaches and to
determine whether the benefits outweigh the costs.
In this work, we therefore evaluated the dosimetric benefit of
the two developed methods for online-adaptive IMPT by compar-
ing them to a robust treatment planning approach. To this end,
we first derived the robustness settings and magnitude of the
safety margins needed to yield adequate target volume coverage
in a set of prostate cancer patients with repeat CT scans. Secondly,
for each fraction we compared the online-adaptive approaches to
the recomputed robust treatment plans in terms of target coverage
and OAR dose.Methods and materials
Patient data
This study included data of 11 prostate cancer patients, with 8–
10 available repeat CT scans per patient selected from a phase II
dose-escalation trial approved by the western Norway regional
committee for medical and health research ethics (2006-15727).
The original planning CT scans were excluded, as these were gen-
erated using contrast fluid, making dose calculation inaccurate.
Taking instead the first repeat CT scan as planning CT scan (pCT),
88 repeat CT scans (rCTs) remained for evaluation. From here on,
pCT refers to the first repeat CT scan being used as planning CT.Treatment planning volumes and prescription
Dose was prescribed according to a simultaneously-integrated
boost scheme comprising a high-dose region of 74 Gy(RBE) and a
low-dose region of 55 Gy(RBE), to be delivered in 37 fractions,
using an RBE of 1.1. An intermediate target dose-region, generated
as the 15 mm transition between the high- and low-dose regions,
was assigned a dose between 55 and 74 Gy(RBE) to steer dose fall-
off. On each scan two clinical target volumes (CTVs) were delin-
eated. For the high-dose region, a CTVHigh was defined as the pros-
tate, a CTVLow was defined for the low-dose region as the lymph
nodes and seminal vesicles. From here on we will denote the com-
bination of the CTVHigh and the CTVLow as CTV. The rectum, bladder,
small and large intestines, and the femoral heads were defined as
OARs. Target delineations were available in all rCTs, OAR delin-
eations in most. For scans missing the delineations of the intestines
or femoral heads the pCT delineations were projected onto the rCT.
Dose was to be delivered with two laterally opposed beams.
All rCTs were aligned to the corresponding pCT by a translation
based on implanted intra-prostatic markers.
Both adaptation strategies require a prior treatment plan gener-
ated on the pCT to start the adaptation. These prior plans were gen-
erated using the PTVPrior structures, which were generated by
enlarging the CTVHigh of the pCT by 7 mm, and the CTVLow by
10 mm. Relatively large margins were selected to ensure sufficient
spot coverage for most target deformations seen in the rCTs, as was
done in previous work [10].Mitigation strategies
Three mitigation strategies were compared in this study, all
aiming for a clinically acceptable dose in all treatment fractions. Strategy A – Robust treatment planning: On each pCT a robust
treatment plan was generated. To account for internal organ
motion with respect to the daily alignment on the markers, tar-
gets were expanded by safety margins creating internal target
volumes (ITVs). Subsequently, robust optimization was applied
using the ‘minimax’ worst-case approach [4–6], including range
robustness to account for uncertainties in the conversion from
Hounsfield units to proton stopping power and including setup
robustness to account for patient shifts relative to the daily
alignment. Nine error scenarios were optimized simultaneously
(nominal, setup, range). We derived the robustness settings
and magnitude of the safety margins required for this dataset to
ensure adequate coverage in all target regions of all rCTs for at
least 90% of the patients. This was done by systematically
increasing the margins (0–8 mm in steps of 2 mm) and the
setup error (2–8 mm in steps of 2 mm), while evaluating the
effect on the rCTs. The range error, related to uncertainties in
the stopping power prediction, was fixed at 3%. For more details
see the Supplementary Materials. CTV coverage of the rCTs was
evaluated by a forward dose calculation of the robust treatment
plan on each rCT.
 Strategy B – Plan restoration: For each rCT the dose distribution
of the prior treatment plan, optimized on the pCT, was restored.
This was done using the delineations of the pCT projected onto
the rCT. The restoration method uses energy-adaptation fol-
lowed by a fast spot-intensity re-optimization focusing on the
targets. Details on this method can be found in [8]. Evaluation
was done on the CTV structures of the rCTs.
 Strategy C – Full plan adaptation: For each rCT, the prior plan
optimized on the pCT was used as a warm-start for adaptation.
The method starts with an energy-adaptation, followed by add-
ing 2500 new spots and a spot-intensity optimization using the
Reference Point Method (RPM). To account for uncertainties in
stopping power prediction the optimization is robust to a 
3%-range. Adaptation is done based on the available contours
in the rCTs. To account for inevitable segmentation errors as
well as intra-fraction motion uncertainties, the CTV contours
were expanded by small margins creating PTVOAPT structures
(Online-Adaptive Proton Therapy). As was done in previous
work, a 2 mm margin was added around the CTVHigh of the
rCT and a 3.5 mm margin was added around the CTVLow [10].
Parameter tuning for this strategy was done using three-fold
cross validation, where one third of the patients (selected ran-
domly) was used for tuning and the remaining two thirds for
testing. Evaluation was done on all folds simultaneously, i.e.
176 plans (two per scan). A brief explanation of the RPM and
the tuning is shown in the Supplementary Materials. Details
on the full adaptation method can be found in [10,12]. Evalua-
tion was done on the PTVOAPT structures of the rCTs.
Note that evaluation of the three strategies is done on different
target definitions, i.e. the daily CTVs for robust planning (A) and
simple dose restoration (B) and the PTVOAPT for full plan adaptation
(C). This was done to include segmentation errors that are inevita-
ble in an online-adaptive approach, thereby avoiding a too opti-
mistic evaluation for strategy C.
The prior and robust treatment plans were generated using our
in-house developed multi-criteria treatment planning system
‘Erasmus-iCycle’ combined with the ‘Astroid’ dose engine. All plans
were optimized to obtain clinically acceptable target coverage
defined as V95%  98% while simultaneously aiming for V107% 
2% for their respective PTV and ITV. Here V95% and V107% are the
percentages of the volumes receiving respectively 95% and 107%
of the prescribed dose. Dose to the OARs was minimized according
to the objectives shown in Table S1 (Supplementary Materials).
Fig. 1. Summary of the compared strategies.
230 Online-adaptive IMPT versus robust IMPTMore details can be found in [15–20]. Fig. 1 summarizes the com-
pared methods.Comparison and evaluation of the methods
For each rCT, the dose distributions obtained with the three
strategies were checked visually and whether they fulfilled the tar-
gets planning criteria. We report the targets V95%, V107% and V110%.
In case of hotspots we also report the D2% and Dmax. For the rectum,
we report the V75Gy RBEð Þ, V60Gy RBEð Þ, V45Gy RBEð Þ, Dmean and D2% and for
the bladder the V65Gy RBEð Þ, V45Gy RBEð Þ, Dmean and D2%. For the whole
body (patient) we report theV10GyðRBEÞ and D2%. Here VxGy RBEð Þ is the
percentage of the volume receiving x Gy(RBE), Dmean is the average
dose and Dmax is the maximum dose.
All calculations were performed on a dual Intel Xeon E5-2690
server.Statistical analysis
Wilcoxon signed-rank tests were performed using MATLAB
(Mathworks version 2017a) to evaluate the differences between
the strategies. A p-value <0.05 was considered to be statistically
significant.Results
For robust treatment planning (A), expanding the CTVHigh and
CTVLow with a 4 mm and 8 mm safety margin, respectively and
applying a range error of 3% and a setup error of 6 mm to the tar-
gets during robust optimization yielded adequate target coverage
(V95%  98% for all target regions) for all rCTs in 10/11 patients.
The other patient had 98% > V95%  95:5% for the CTVLow for 3/8
rCTs.
Applying the robust treatment plans on the rCTs resulted in a
population-mean V107% of the CTVLow of 44.8% (19.5%–60.9%) and
a population-mean V110% of 19.9% (5.6%–37.6%). D2% values up to
65.8 Gy(RBE) and Dmax values up to 75.1 Gy(RBE) were obtained
(respectively 119.6% and 136.5% of 55 Gy(RBE)). These high values
are due to the proximity of the ITVHigh and ITVLow, as during robust
optimization the dose in the ITVLow is increased to achieve ade-
quate ITVHigh coverage in the error scenarios.
For the CTVHigh all scans obtained V107%  2% and V110% ¼ 0%.
No combination of margins and robustness was found obtaining
sufficient coverage for all target regions for all rCTs of all patients.
Applying plan restoration (B) yielded V95%  98% for all scans.
For the CTVHigh all scans obtained V107%  2%, but for the CTVLow
21/88 scans obtained V107% > 2%, with values up to 3.7%. D2%
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obtained (respectively 108.4% and 130.4% of 55 Gy(RBE)). All 88
scans obtained V110% ¼ 0% for the CTVHigh, but
0% < V110% < 1:6% for the CTVLow.
Applying the full plan adaptation method (C) yielded
V95%  98% for all plans for the PTVOAPT_High and PTVOAPT_Low. For
the PTVOAPT_High 54/176 plans obtained V107% > 2% (up to 37.3%)
and 9/176 plans V110% > 0% (up to 15.2%). D2% values up to
84.0 Gy(RBE) and Dmax values up to 85.3 Gy(RBE) (respectively
113.5% and 115.3% of 74 Gy(RBE)) were obtained. For the
PTVOAPT_Low 20/176 plans obtained V107% > 2% (up to 13.7%), with
D2% and Dmax values up to 59.9 Gy(RBE) (108.9% of 55 Gy(RBE)).
All plans obtained V110% ¼ 0%.
In terms of OAR sparing the adaptive strategies (B and C) outper-
formed strategy A for all patients. Fig. 2 shows boxplots depicting
the obtained OAR values for the three strategies. Largest differences
between the strategies were observed for the V45Gy RBEð Þ of both rec-
tum and bladder. For the rectum the median value improved with
11.1%-point when moving from robust treatment planning to plan
restoration (A to B) and 16.3%-point whenmoving to full plan adap-
tation (A to C). For the bladder these improvements were respec-
tively 6.9%-point and 9.9%-point. For the high dose criteria
(V75GyðRBEÞ, D2% and Dmax) smaller differences between the strategies
were observed. For all evaluation criteria of theOARs the differences
between robust treatment planning (A) and plan restoration (B), as
well as the differences between plan restoration (B) and full plan
adaptation (C) were statistically significant.
Fig. 3 shows an example of a slice of the dose distributions
obtained for one of the rCTs using the three different strategies.
It can be seen that the high-dose region is largest for robust treat-
ment planning (A) and smallest for plan adaptation (C).
Plan restoration (B) took on average 1.7 min (1.4–2.1) and full
plan adaptation (C) took on average 6.6 min (5.0–9.8). These times
include the adaptation steps and intermediate dose calculations,
but exclude initialization and final dose calculation, thus reflecting
the additional time required compared to recalculation of a static
plan on the rCT (strategy A). For both methods, the initialization
consumed on average ~1 min. The final dose calculation takes on
average 3.9 min for plan restoration (2.1–5.5) and 7.0 min for full
adaptation (3.1–11.3).Fig. 2. Boxplots depicting the obtained dosimetrDiscussion
In this study, robust treatment planning combined with safety
margins (A) was compared to two adaptive strategies (B and C).
Plan restoration and full plan adaptation both achieved
V95%  98% for all rCTs, while robust treatment planning did not
meet this criteria for one patient. Applying adaptive treatment
planning always resulted in lower OAR doses than robust treat-
ment planning, with largest median improvements observed for
the rectum (up to 16.3%-point). Several studies have shown OAR
dose to be correlated to toxicity [21], so lowering these with
online-adaptive IMPT can potentially reduce the expected toxici-
ties compared to a strategy that fully relies on robust treatment
planning.
For the robust treatment planning approach we derived
required margins and robustness settings to achieve adequate tar-
get coverage for all rCTs in at least 90% of the patients. We obtained
five combinations of margins and robustness settings all yielding
adequate target coverage for all rCTs of 10/11 patients. For this
study, we selected the combination with the smallest margins
and robustness settings. It should be noted that these settings
are specific to the investigated dataset and the number of robust-
ness scenarios and have not been validated on other datasets.
The observed benefit of adaptive planning likely depends on the
dataset and robustness settings that are used.
In this study both targets were robustly optimized using the
same values for setup and range robustness to stay close to clinical
practice. More research is needed to determine whether OAR doses
could be reduced by applying target-specific robustness settings.
The effect of fractionation has not been considered in this study.
Fractionation can potentially average out underdosage or over-
dosage in the target volume. Hence, the evaluation criteria applied
in this study for the three strategies might be too conservative.
However, while uncertainties in photon radiotherapy mostly result
in dose deviations around the target-edges, IMPT can result in
underdosage in the center of the target. Whether an underdosage
in the center of the target volume can be effectively compensated
by an overdosage in another fraction is unclear. Besides this, treat-
ments are increasingly delivered in fewer fractions reducing the
averaging effect [22].ic parameter values for the three strategies.
Fig. 3. An example of the dose distributions obtained using the different strategies for one repeat CT scan. The red contour indicates the daily CTVHigh.
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were used, as these have shown to be effective in previous work
[10]. Changing these prior margins and changing the PTVOAPT mar-
gins may influence the observed gain of adaptive planning. Fur-
thermore, due to the used optimization method, the plans
obtained through simple dose restoration are not explicitly made
robust against range errors caused by uncertainties in stopping
power prediction. While setup errors should be negligible in the
daily adaptive workflow, range errors arising from Hounsfield Unit
to proton stopping power conversion remain present. For full plan
adaptation, we have therefore included range robustness in the
spot-weight optimization. The tuning of the RPM-parameters how-
ever has been done without including range robustness. This could
be an explanation for the elevated V107% values obtained with full
plan adaptation. Including range robustness in the tuning could
possibly reduce these, although from a clinical perspective these
values are acceptable.
In this study the three methods have been compared for a data-
set of high-risk prostate cancer patients. This treatment group is
interesting for online-adaptive planning due to the challenges
which are related to the size of the target volume, its location in
the pelvic region, and the differential motion between the low-
dose and high-dose target volumes. Investigating the benefit of
online-adaptive planning in other treatment sites such as head
and neck cancer and locally advanced cervical cancer and lung can-
cer is part of ongoing and future research.
All treatment plans were made using two laterally opposed
beams. While more complex beam geometries might improve all
three methods, finding such a geometry requires further research.
For all methods the CTs were aligned based on intra-prostatic
markers. This approach may differ between centres. The accuracy
of alignment might influence the required setup robustness and
margins. However, as the alignment was the same for all methods,
no effect on the comparison is expected.
Intra-fraction variations have not been addressed in this study.
However, we included a small margin (2.0/3.5 mm) to account for
the extra intra-fractional motion potentially occurring between
the start of the full adaptation and beam delivery and to account
for segmentation uncertainties. Intra-fraction motion during beam
delivery was ignored for all three methods, but could easily be
included by expanding the PTV or ITV or increasing robustness.
Whether the includedmargins are sufficient or whether largermar-
gins or more robustness is required was outside the scope of this
study and should be investigated before clinical implementation.
General challenges of introducing online-adaptive IMPT into the
clinic include adaptation time, user interaction time, the need for
daily delineations and plan quality assurance (QA). Considering
the adaptation time, the fully automated process now takes on
average 2.9 min for dose restoration, and 7.5 min for full adapta-
tion. As anatomical variations could occur during this time span,
calculation times should be further reduced. The intermediate dose
calculations are the most time consuming. Dose calculation timecan be shortened considerably for example by parallelization and
running the calculations on a GPU, as shown by Silva et al.
[23,24] and Matter et al. [13]. This was however outside the scope
of this study. Regarding the user interaction time, as both investi-
gated adaptive strategies are fully automated, user interaction is
only required once in advance to tune the parameters for an entire
patient population, and once prior to each fraction to verify and
approve the adaptation. The latter can be automated as well by
automatically computing relevant dosimetric parameter values of
the adapted plan and checking these against predefined limits.
Prior to adaptation however the delineations of the rCT should
be generated. When done manually, this step requires time-
consuming user interaction. This can be largely avoided by (partly)
generating the daily delineations automatically. For prostate can-
cer patients, an auto-propagation method combining deep-
learning with deformable image registration has for example been
developed with which already 80% of the automatically propagated
pCT contours onto the rCT could be used without manual correc-
tions [25]. Without deep-learning, contour propagation was used
in for example the work on adaptive planning by Kurz et al. and
Botas et al. [7,11]. Additional uncertainties in automatically gener-
ated contours can be accounted for by adding a margin to the tar-
gets as was done in the present study. It should be noted that daily
delineations are only needed for full plan adaptation, as plan
restoration uses the pCT contours. Another challenge lies in daily
plan QA, for which little to no time is available in the daily adaptive
workflow. This can be solved using alternatives such as a redun-
dant dose calculation, online dose monitoring using prompt
gamma emission profiles [26], and using machine log files
[27,28] to verify the correct delivery of the treatment plan.
In conclusion, having demonstrated that plan adaptation in
IMPT can reduce dose to OARs compared to robust treatment plan-
ning within a clinically acceptable time frame, we consider it aus-
picious to start exploring clinical implementation of online-
adaptive strategies in IMPT.Acknowledgements
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